Early clinical data are emerging for mutant KRAS (mKRAS)-targeted peptide vaccination designed to intercept pancreatic ductal adenocarcinoma (PDAC) in high-risk cohorts. In a Phase I first-in-human study (NCT05013216), researchers reported that 18 of 20 participants developed mKRAS-specific T-cell responses after vaccination, and T-cell receptor clonotypes persisted for up to two years. Across a median follow-up of 16.5 months, the study reported no PDAC diagnoses among participants during the observation window, supporting advancement toward KRAS-targeted interception strategies. Adverse events were grade 1–2, with the main emphasis on safety, immunogenicity, and durability of the cellular response. A parallel early prevention readout also describes vaccine activity in high-risk patients, reinforcing that immune-focused strategies are moving beyond treatment into risk-reduction for PDAC populations where surveillance detects only a minority of precursor lesions.